Effect of dexmedetomidine on kidney function during heart surgery
The Effect of Intraoperative Dexmedetomidine on Renal Function After Coronary Artery Bypass Graft Surgery
This study tests if giving dexmedetomidine during heart surgery can help protect kidney function in patients undergoing coronary artery bypass graft surgery.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Novi Sad Academic / other |
| Locations | 1 site (Novi Sad) |
| Trial ID | NCT06378827 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the impact of administering dexmedetomidine during coronary artery bypass graft surgery on patients' renal function. It involves a randomized approach where participants are divided into experimental and control groups. Prior to surgery, comprehensive assessments including demographic data, echocardiography, and various laboratory tests will be conducted to evaluate baseline health. The study aims to gather data on how dexmedetomidine affects kidney health post-surgery.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years scheduled for elective coronary artery bypass graft surgery with an ASA score of 3 or 4.
Not a fit: Patients undergoing emergency surgery, those with chronic renal failure, or significant heart block may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved kidney function outcomes for patients undergoing heart surgery.
How similar studies have performed: Previous studies have shown promising results with dexmedetomidine in similar surgical contexts, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Elective coronary artery bypass graft surgery * Age over 18 years * ASA score 3 or 4 * Voluntary consent of the patient to participate in the research Exclusion Criteria: * Emergency coronary artery bypass graft surgery * Chronic renal failure with eGFR \<60 ml/min/1.73m2 * Left ventricular ejection fraction \<30% * 2nd or 3rd degree atrioventricular block * Use of nephrotoxic agents such as aminoglycoside antibiotics or contrast agents within the last 48 hours * Previous heart surgery or kidney surgery * Allergy to dexmedetomidine
Where this trial is running
Novi Sad
- University of Novi Sad, Faculty of Medicine — Novi Sad, Serbia (Recruiting)
Study contacts
- Study coordinator: Ranko Zdravkovic
- Email: ranko.zdravkovic@mf.uns.ac.rs
- Phone: +381654674620
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.